FDA stamps fast OK on Astellas' pioneering FLT3 AML drug gilteritinib, expanding on a record year for new approvals
Astellas has picked up boasting rights to gaining the first FDA approval of a FLT3 inhibitor for a specific group of FLT3 positive acute myeloid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
